Clinical trials: Gluten Enteropathy
Celiac Disease
PRV-015 in Gluten-free Diet Non-responsive Celiac Disease
This study will evaluate the efficacy and safety of PRV-015 in adult patients with non-responsive celiac disease (NRCD) who are on a gluten-free diet (GFD).
- Trial name
- PROACTIVE (NCT04424927)
- Testing
- PRV-015
- Where
- 38 sites in United States, Canada and 2 more
- Volunteers
- 388 people
- Sponsor
- Provention Bio, a Sanofi Company
Celiac Disease
A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease
This study is designed to evaluate the efficacy and safety of AMG 714 for the attenuation of the effects of gluten exposure in adult patients with celiac disease during a gluten challenge.
- Trial name
- NCT02637141
- Testing
- AMG 714, Gluten Challenge
- Where
- 3 sites in Finland
- Volunteers
- 64 people
- Sponsor
- Amgen
Celiac Disease
Gluten Challenge Study in Celiac Disease Participants (MK-0000-402)
This is a gluten challenge study to characterize peripheral blood and intestinal gluten specific cluster of differentiation 4 glycoprotein (CD4+) thymus lymphocyte (T cell) subsets in participants with Celiac Disease
- Trial name
- NCT04054544
- Testing
- Gluten powder 4g
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma
Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease
Protocol CELIM-RCD-002 is designed to evaluate the efficacy and safety of AMG 714 for the treatment of adult patients with type II refractory celiac disease (RCD-II), an in-situ small bowel T-cell lymphoma.
- Trial name
- NCT02633020
- Testing
- AMG 714
- Where
- 6 sites in United States, Finland and 3 more
- Volunteers
- 28 people
- Sponsor
- Amgen
Celiac Disease
Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
This study is to characterize the safety and tolerability of an investigational drug called TIMP-GLIA when either one or two intravenous doses are given to subjects with celiac disease.
- Trial name
- NCT03486990
- Testing
- TIMP-GLIA
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Takeda
Celiac Disease
Serum Markers in Gluten Challenge
1. The purpose of this research study is to evaluate non-invasive markers of celiac disease activity in subjects that are on a gluten-free diet, in remission from celiac disease who undergo gluten challenge. 2.
- Trial name
- NCT00931892
- Testing
- Gluten
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Beth Israel Deaconess Medical Center
Celiac Disease
Evaluate the Use of Optical Frequency Domain Imaging (OFDI) for Celiac Disease in Children, Adolescents and Young Adults
The goal of this research is to conduct a pilot clinical study to image Celiac disease characteristic mucosal lesions and compare Optical Frequency Domain Imaging (OFDI) images to histologic evaluation in children, adolescents…
- Trial name
- NCT01439035
- Testing
- MGH OFDI Imaging
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Cancer
Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study
The purpose of this study is to obtain preliminary safety and efficacy data after endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) in patients with locally advanced or unresectable pancreatic adenocarcinoma.
- Trial name
- NCT00578279
- Testing
- dehydrated alcohol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Celiac Disease, Coeliac Disease
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole
This is a 3-part first time into human study (FTIH) study for GSK3915393. Parts A and B of the study will evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending and repeat oral doses of GSK3915393 in…
- Trial name
- NCT04604795
- Testing
- GSK3915393 Capsules, GSK3915393 Solution for Infusion, Itraconazole
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Celiac Disease
Assessment of KAN-101 in Celiac Disease (ACeD)
A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2.
- Trial name
- NCT04248855
- Testing
- KAN-101
- Where
- 13 sites in United States
- Volunteers
- 41 people
- Sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Celiac Disease
Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease
Celiac disease is a condition in which the small intestine is damaged by gluten, the storage protein of wheat and similar proteins in barley and rye.
- Trial name
- NCT01137955
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Celiac Disease
Desensitising Celiac Disease Patients With the Human Hookworm
We have established that the hookworm Necator americanus (Na) dramatically alters the local and systemic immune landscape of the infected human host.
- Trial name
- NaCeD (NCT01661933)
- Testing
- Necator americanus
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- The Prince Charles Hospital
Celiac Disease
Oral AGY for Celiac Disease
Celiac disease (CD) is an autoimmune disease of the small intestine caused by the consumption of gluten proteins from widely used food sources such as wheat, rye, and barley.
- Trial name
- NCT01765647
- Testing
- AGY
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Igy Inc.
Celiac Disease
Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge
The primary purpose of this study is to characterize changes in gluten-specific T cells and pathology in the small intestine with specific focus on biomarkers likely to change with therapeutic celiac disease (CeD) treatment.
- Trial name
- NCT03409796
- Testing
- Gluten
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Takeda
Celiac Disease
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).
- Trial name
- NCT05574010
- Testing
- Cohort 1 in Part A, Cohort 2 in Part A, Group 2 in Part B and Part C
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 128 people
- Sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Celiac Disease
Pancreatic Enzyme Supplementation for Celiac Disease
The purpose of this protocol is to conduct a pilot study to investigate whether pancreatic enzyme supplementation will improve symptoms in individuals with celiac disease who suffer persistent symptoms despite a gluten free diet.
- Trial name
- NCT02475369
- Testing
- pancrelipase
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Beth Israel Deaconess Medical Center
Celiac Disease
Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease (CeD) on a gluten-free diet (GFD).
- Trial name
- NCT04530123
- Testing
- TAK-101, Gluten
- Where
- 48 sites in United States, Australia and 2 more
- Volunteers
- 102 people
- Sponsor
- Takeda
Down Syndrome
An Online Health Tool About Down Syndrome: Down Syndrome Clinic to You
The investigators conducted a national two-arm, randomized controlled trial of caregivers of individuals with DS to assess the efficacy of DSC2U in assuring adherence to evidence-based guidelines.
- Trial name
- DSC2U (NCT04227197)
- Testing
- Down Syndrome Clinic to You (DSC2U)
- Where
- United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Irritable Bowel Syndrome
Dietary Triggers of Gastrointestinal Symptoms in IBS Patients
This crossover randomized controlled trial will evaluate the effects of purified gluten and whole wheat (gluten combined with amylase-trypsin inhibitors (ATIs)) on inducing intestinal and extra-intestinal symptoms in irritable…
- Trial name
- NCT03664531
- Testing
- Purified gluten, Non-purified gluten (containing ATIs)
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- McMaster University
Chronic Pancreatitis
CPB Versus Sham Treatment for Pain Management in Small Duct Chronic Pancreatitis
This study assesses the pain response to Endoscopic Ultrasound (EUS) guided Celiac Plexus Block (CPB) treatment in comparison to EUS without a pain block administered. All participants will receive medications for pain as needed.
- Trial name
- NCT02054910
- Testing
- Celiac Plexus Block
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham